Results 271 to 280 of about 1,309,818 (329)

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

open access: yesAdvanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang   +13 more
wiley   +1 more source

Bovine leukaemia virus genotypes 5 and 6 are circulating in cattle from the state of São Paulo, Brazil

open access: green, 2017
Lílian Gregory   +8 more
openalex   +1 more source

CD168 Identifies Proliferating Pancreatic Islet Cells in Murine and Human

open access: yesAdvanced Science, EarlyView.
This study identifies CD168 as a conserved surface marker for proliferating β‐cells in mouse, human islets, and pancreatic islet tumors. CD168⁺ cells show high proliferation and low insulin expression. CD168+ cells form mostly uni‐β lineage clones, and some of the clones are multi‐lineage.
Shubo Yuan   +21 more
wiley   +1 more source

Targeting Itga8 Mitigates Neurogenic Bladder Fibrosis Driven by Trem2⁺ Macrophage‐Derived Fn1 via FAK/RhoA/ROCK Signaling

open access: yesAdvanced Science, EarlyView.
Normal bladders exhibit quiescent fibroblasts/macrophages, whereas neurogenic bladders show acute‐phase Itga8⁺ fibroblast expansion driven by Trem2⁺ macrophage‐secreted Fn1, which activates FAK/RhoA/ROCK signaling, promotes cytoskeletal remodeling, and upregulates pro‐fibrotic genes.
Jiaxin Wang   +9 more
wiley   +1 more source

An Automated Organotypic SCN Culture System Revealing Novel Insights into VIP Regulation of Circadian Rhythm

open access: yesAdvanced Science, EarlyView.
An Automated ex vivo culture system BaSIC, tailored for SCN slices and cell culture, which automates medium exchange and ensures a stable internal environment is developed. BaSIC enables real‐time observation of tissue/cell responses to diverse but programmed stimuli.
Kui Han   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy